Nanodevices in diagnostics

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 3, Issue 1, 2011, Pages 11-32

  Hu, Ye ^a   Fine, Daniel H ^b   Tasciotti, Ennio ^b   Bouamrani, Ali ^b   Ferrari, Mauro ^a,b,c,d,e  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Rice University   (United States)

^e Alliance for NanoHealth   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIO-MARKER DISCOVERY; CLINICAL APPLICATION; CLINICAL PRACTICES; COMPOSITIONAL HETEROGENEITY; DIAGNOSTIC MODALITY; DIAGNOSTIC TECHNOLOGIES; DISEASE MONITORING; EARLY-STAGE DIAGNOSIS; HIGHLY SENSITIVE; INTERDISCIPLINARY COLLABORATIONS; MODERN MEDICINE; MOLECULAR DETECTION; NANO SCALE; NANO-DEVICES; NANO-MATERIALS; NANO-SCALE MATERIALS; SUB-CELLULAR;

NANOSTRUCTURED MATERIALS;

DIAGNOSIS;

APTAMER; BIOLOGICAL MARKER; DENDRIMER; GOLD; NANOMATERIAL; NANOPARTICLE; NANOWIRE; QUANTUM DOT;

BIOSENSOR; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; NANOANALYSIS; NANODEVICE; NANOTECHNOLOGY; PRIORITY JOURNAL; PROTEOMICS; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; DIAGNOSTIC EQUIPMENT; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NANOPARTICLES; NANOTECHNOLOGY;

EID: 78650651462     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.82     Document Type: Review

References (144)

1. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996, 69: 135-174.
2. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism 2008, 7: 11-20.
3. Cheng MMC, Cuda G, Bunimovich YL, Gaspari M, Heath JR, et al. Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol 2006, 10: 11-19.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58: 71-96.
5. Tabár L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, et al. Reduction in mortality from breast cancer after mass screening with mammography. Lancet 1985, 1: 829-832.
6. Berg WA, Gutierrez L, NessAiver MS, Carter WB, Bhargavan M, et al. Diagnostic accuracy of mammography, clinical examination, us, and MR Imaging in preoperative assessment of breast cancer. Radiology 2004, 233: 830-849.
7. Pleotis HL, Lynne LC. Cytomorphology of common malignant tumors of the breast. Clin Lab Med 2005, 25: 733-760.
8. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1: 845-867.
9. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359: 572-577.
10. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2005, 116: 26-30.
11. Levenson VV. Biomarkers for early detection of breast cancer: what, when, and where? Biochim Biophys Acta 2007, 1770: 847-856.
12. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 2005, 102: 2273-2276.
13. Gao X, Cui Y, Levenson RM, Chung LWK, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004, 22: 969-976.
14. Wu X, Liu H, Liu J, Haley KN, Treadway JA, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 2002, 22: 41-46.
15. Lee JH, Huh YM, Jun YW, Seo JW, Jang JT, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 2007, 13: 95-99.
16. Na HB, Lee JH, An K, Park YI, Park M, et al. Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew Chem Int Ed Engl 2007, 46: 5397-5401.
17. Hanahan D, Weinberg RA. The hallmarkers of cancer. Cell 2000, 100: 57-70.
18. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286: 531-537.
19. Liotta LA, Petricoin EF. Molecular profiling of human cancer. Nat Rev Genet 2000, 1: 48-56.
20. Sikora K. Personalized medicine for cancer: from molecular signature to therapeutic choice. Adv Cancer Res 2007, 96: 345-369.
21. Srinivas PR, Kramer BS, Srivastava S. Trends in biomarker research for cancer detection. Lancet Oncol 2001, 2: 698-704.
22. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002, 2: 210-219.
23. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403: 503-511.
24. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439: 353-357.
25. Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, et al. Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res 2003, 13: 2363-2371.
26. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 2005, 437: 1173-1178.
27. Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck F, et al. Human protein-protein interaction network: a resource for annotating the proteome. Cell 2005, 122: 957-968.
28. Chambers G, Lawrie L, Cash P, Murray GI. Proteomics: a new approach to the study of disease. J Pathol 2000, 192: 280-288.
29. James P. Protein identification in the post-genome era: the rapid rise of proteomics. Q Rev Biophys 1997, 30: 279-331.
30. Riera C, Fisa R, Udina M, Gallego M, Portus M. Detection of Leishmania infantum cryptic infection in asymptomatic blood donors living in an endemic area (Eivissa, Balearic Islands, Spain) by different diagnostic methods. Trans R Soc Trop Med Hyg 2004, 98: 102-110.
31. De Paepe B, Smet J, Lammens M, Seneca S, Martin JJ, et al. Immunohistochemical analysis of the oxidative phosphorylation complexes in skeletal muscle from patients with mitochondrial DNA encoded tRNA gene defects. J Clin Pathol 2009, 62: 172-176.
32. Joos TO, Schrenk M, Höpfl P, Kröger K, Chowdhury U, et al. A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics. Electrophoresis 2000, 21: 2641-2650.
33. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool-opportunities and potential limitations. Mol Cell Proteomics 2004, 3: 367-378.
34. Wu X, Liu H, Liu J, Haley KN, Treadway JA, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 2003, 21: 41-46.
35. Haes AJ, Van Duyne RP. A nanoscale optical blosensor: sensitivity and selectivity of an approach based on the localized surface plasmon resonance spectroscopy of triangular silver nanoparticles. J Am Chem Soc 2002, 124: 10596-10604.
36. Jain KK. Nanotechnology in clinical laboratory diagnostics. Clin Chim Acta 2005, 358: 37-54.
37. Buxton DB, Lee SC, Wickline SA, Ferrari M. National Heart, Lung, and Blood Institute Nanotechnology Working Group. Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group. Circulation 2003, 108: 2737-2742.
38. Khademhosseini A, Langer R. Nanobiotechnology-drug delivery and tissue engineering. Chem Eng Prog 2006, 102: 38-42.
39. Liotta LA, Ferrari M, Petricoin EF. Written in blood. Nature 2003, 425: 905.
40. Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006, 6: 961-967.
41. Görg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004, 4: 3665-3685.
42. Terracciano R, Gaspari M, Testa F, Pasqua L, Tegliaferri P, et al. Selective binding and enrichment for low-molecular weight biomarker molecules in human plasma after exposure to nanoporous silica particles. Proteomics 2006, 6: 3243-3250.
43. Geho D, Cheng MMC, Killian K, Lowenthal M, Ross S, et al. Fractionation of serum components using nanoporous substrates. Bioconjug Chem 2006, 17: 654-661.
44. Gaspari M, Cheng MMC, Terracciano R, Liu X, Nijdam AJ, et al. Nanoporous Surfaces as Harvesting agents for mass spectrometric analysis of peptides in human plasma. J Proteome Res 2006, 5: 1261-1266.
45. Lu Y, Ganguli R, Drewien CA, Anderson MT, Brinker CJ, et al. Continuous formation of supported cubic and hexagonal mesoporous films by sol-gel dip-coating. Nature 1997, 389: 364-368.
46. Zhao D, Yang P, Melosh N, Feng J, Chmelka BF, et al. Continuous mesoporous silica films with highly ordered large pore structures. Adv Mater 1998, 10: 1380-1385.
47. Wan Y, Shi Y, Zhao D. Designed synthesis of mesoporous solids via nonionic-surfactant-templating approach. Chem Commun 2007, 9: 897-926.
48. Sanchez C, Boissière C, Grosso D, Laberty C, Nicole L. Design, synthesis, and properties of inorganic and hybrid thin films having periodically organized nanoporosity. Chem Mater 2008, 20: 682-737.
49. Nobel prize history. games/physics/transistor/history/.
50. Bergveld P. Development, operation and application of the ion-sensitive field effect transistor as a tool for electrophysiology. IEEE Trans Biomed Eng 1972, BME-19: 342-351.
51. Blackburn GF. In: Turner APF, Karube I, Wilson GS, eds. Biosensors: Fundamentals and Applications. Oxford: Oxford University Press; 1987, 481-530.
52. Cui Y, Wei Q, Park H, Lieber CM. Nanowire nanosensors for highly sensitive and selective detection of biological and chemical species. Science 2001, 293: 1289-1292.
53. Patolsky F, Timko BP, Zheng G, Lieber CM. Nanowire-based nanoelectric devices in the life sciences. MRS Bull 2007, 32: 142-149.
54. Patolsky F, Zheng G, Lieber CM. Nanowire-based biosensors Anal Chem 2006, 78: 4260-4269.
55. Patolsky F, Zheng G, Lieber CM. Fabrication of silicon nanowire devices for ultrasensitive, label-free, real-time detection of biological and chemical species. Nat Protoc 2006, 1: 1711-1724.
56. Zhang J, Lang HP, Huber F, Bietsch A, Grange W, et al. Rapid and label-free nanomechanical detection of biomarker transcripts in human RNA. Nat Nanotechnol 2006, 3: 214-220.
57. Zheng G, Patolsky F, Cui Y, Wang WU, Lieber CM. Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat Biotechnol 2005, 23: 1294-1301.
58. Bunimovich YL, Shin YS, Yeo W-S, Amori M, Kwong G, et al. Quantitative real-time measurements of DNA hybridization with alkylated nonoxidized silicon nanowires in electrolyte solution. J Am Chem Soc 2006, 128: 16323-16331.
59. Hinman AR. Global progress in infectious disease control. Vaccine 1998, 16: 1116-1121.
60. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11: 5678-5685.
61. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6: 857-866.
62. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009, 11: 228-234.
63. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, et al. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev 2006, 20: 2202-2207.
64. Zhang GJ, Chua JH, Chee RE, Agarwal A, Wong SM. Links Label-free direct detection of MiRNAs with silicon nanowire biosensors. Biosens Bioelectron 2009, 24: 2504-2508.
65. Lee HS, Kim KS, Kim CJ, Hahn SK, Jo MH. Links Electrical detection of VEGFs for cancer diagnoses using anti-vascular endothelial growth factor aptamer-modified Si nanowire FETs. Biosens Bioelectron 2009, 24: 1801-1805.
66. Lieber CM, Wang ZL. Functional nanowires. MRS Bull 2007, 32: 99-108.
67. Melosh NA, Boukai A, Diana F, Gerardot B, Badolato A, et al. Ultrahigh-density nanowire lattices and circuits. Science 2003, 300: 112-115.
68. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5: 161-171.
69. Hansen KM, Thundat T. Microcantilever biosensors. Methods 2005, 37: 57-64.
70. Fritz J, Baller MK, Lang HP, Rothuizen H, Vettiger P, et al. Translating Biomolecular Recognition into Nanomechanics. Science 2000, 288: 316-318.
71. Braun T, Barwich V, Ghatkesar MK, Bredekamp AH, Gerber C, et al. Micromechanical mass sensors for biomolecular detection in a physiological environment. Phys Rev E Stat Nonlin Soft Matter Phys 2005, 72: 031907.
72. Kwon TY, Eom K, Park JH, Yoon DS, Kim TS, et al. In situ real-time monitoring of biomolecular interactions based on resonating microcantilevers immersed in a viscous fluid. Appl Phys Lett 2007, 90: 223903.
73. Su M, Li S, Dravid VP. Microcantilever resonance-based DNA detection with nanoparticle probes. Appl Phys Lett 2003, 82: 3562-3564.
74. Zhang J, Lang HP, Huber F, Bietsch A, Grange W, et al. Rapid and label-free nanomechanical detection of biomarker transcripts in human RNA. Nat Nanotechnol 2006, 1: 214-220.
75. Lee JH, Hwang KS, Park J, Yoon KH, Yoon DS, et al. Immunoassay of prostate-specific antigen (PSA) using resonant frequency shift of piezoelectric nanomechanical microcantilever. Biosens Bioelectron 2005, 20: 2157-2162.
76. Wu G, Datar RH, Hansen KM, Thundat T, Cote RJ, et al. Bioassay of prostate-specific antigen (PSA) using microcantilevers. Nat Biotechnol 2001, 19: 856-860.
77. Barry MJ. Screening for prostate cancer-the controversy that refuses to die. N Engl J Med 2009, 360: 1351-1354.
78. Yoon SS, Segal NH, Olshen AB, Brennan MF, Singer S. Circulating angiogenic factor levels correlate with extent and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol 2004, 15: 1261-1266.
79. Kastner MA. The single electron transistor and artificial atoms. Ann Phys 2000, 9: 885-894.
80. Brousseau LC III. Label-free "digital detection" of single-molecule DNA hybridization with a single electron transistor. J Am Chem Soc 2006, 128: 11346-11347.
81. Kastner MA. Artificial atoms. Phys Today 1993, 46: 24-31.
82. Brousseau LC III, Zhao Q, Shultz DA, Feldheim DL. pH-gated single-electron tunneling in chemically modified gold nanoclusters. J Am Chem Soc 1998, 120: 7645-7646.
83. Kronick P, Gilpin RW. Links use of superparamagnetic particles for isolation of cells. J Biochem Biophys Methods 1986, 12: 73-80.
84. Wikström P, Flygare S, Gröndalen A, Larsson PO. Links Magnetic aqueous two-phase separation: a new technique to increase rate of phase-separation, using dextran-ferrofluid or larger iron oxide particles. Anal Biochem 1987, 167: 331-339.
85. Slotkin JR, Cahill KS, Tharin SA, Shapiro EM. Cellular magnetic resonance imaging: nanometer and micrometer size particles for noninvasive cell localization. Neurotherapeutics 2007, 4: 428-433.
86. Vollath D. Nanomaterials: An Introduction to Synthesis, Properties and Applications: Weinheim: Wiley-VCH, 2008, 1-21.
87. Squire LF, Novelline RA. Squire's Fundamentals of Radiology. 5th ed. Cambridge: Harvard University Press; 1997, 36-39.
88. Hurley D. High-field MRI visualizes senile plaque in humans for first time. Neurol Today 2007, 7: 12-13.
89. Corot C, Robert P, Idée JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006, 58: 1471-1504.
90. Molday RS, MacKenzie D. Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. J Immunol Methods 1982, 52: 353-367.
91. Shen T, Weissleder R, Papisov M, Bogdanov A Jr, Brady TJ. Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. Magn Reson Med 1993, 29: 599-604.
92. 4 (M = Fe, Co, Mn) nanoparticles. J Am Chem Soc 2004, 126: 273-279.
93. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 2008, 60: 1252-1265.
94. Zhang Y, Kohler N, Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 2002, 23: 1553-1561.
95. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, et al. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263: 1600-1603.
96. Sun C, Veiseh O, Gunn J, Fang C, Hansen S, et al. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 2008, 4: 372-379.
97. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003, 49: 403-408.
98. Ai H, Flask C, Weinberg B, Shuai X, Pagel MD, et al. Magnetite-loaded polymeric micelles as ultrasensitive magnetic-resonance probes. Adv Mater 2005, 17: 1949-1952.
99. Nasongkla N, Bey E, Ren J, Ai H, Khemtong C, et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett 2006, 6: 2427-2430.
100. Michalet X, Pinaud FF, Bentoilla LA, Tsay JM, Doose S, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307: 538-544.
101. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 2005, 4: 435-446.
102. Kim S, Lim YT, Soltesz EG, De Grand AM, Lee J, et al. Near-infrared fluoresncet type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 2004, 22: 93-97.
103. Azzazy HM, Mansour MM, Kazmierczak SC. From diagnostics to therapy: prospects of quantum dots. Clin Biochem 2007, 40: 917-927.
104. Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307: 538-544.
105. Azzazy HM, Mansour MM, Kazmierczak SC. Nanodiagnostics: a new frontier for clinical laboratory medicine. Clin Chem 2006, 52: 1238-1246.
106. Sukhanova A, Nabiev I. Fluorescent nanocrystal-encoded microbeads for multiplexed cancer imaging and diagnosis. Crit Rev Oncol Hematol 2008, 68: 39-59.
107. Medintz IL, Mattoussi H, Clapp AR. Potential clinical applications of quantum dots. Int J Nanomed 2008, 3: 151-167.
108. Jaiswal JK, Mattoussi H, Mauro JM, Simon SM. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat Biotechnol 2003, 21: 47-51.
109. Goldman ER, Clapp AR, Anderson GP, Uyeda HT, Mauro JM, et al. Multiplexed toxin analysis using four colors of quantum dot fluororeagents. Anal Chem 2004, 76: 684-688.
110. Bailey VJ, Easwaran H, Zhang Y, Griffiths E, Belinsky SA, et al. MS-qFRET: a quantum dot-based method for analysis of DNA methylation. Genome Res 2009, 19: 1455-1461.
111. Jain P, El-Sayed I, El-Sayed M. Au nanoparticles target cancer. Nano Today 2007, 2: 18-29.
112. Willets KA, Van Duyne RP. Localized surface plasmon resonance spectroscopy and sensing. Annu Rev Phys Chem 2007, 58: 267-297.
113. Baptista P, Pereira E, Eaton P, Doria G, Miranda A, et al. Gold nanoparticles for the development of clinical diagnosis methods. Anal Bioanal Chem 2008, 391: 943-950.
114. West JL, Halas NJ. Engineered nanomaterials for biophotonics applications: improving sensing, imaging, and therapeutics. Annu Rev Biomed Eng 2003, 5: 285-292.
115. Wilson R. The use of gold nanoparticles in diagnostics and detection. Chem Soc Rev 2008, 37: 2028-2045.
116. Huang X, El-Sayed IH, Qian W, El-Sayed MA. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc 2006, 128: 2115-2120.
117. Hirsch LR, Jackson JB, Lee A, Halas NJ, West JL. A whole blood immunoassay using gold nanoshells. Anal Chem 2003, 75: 2377-2381.
118. Ghossein RA, Bhattacharya S. Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. Eur J Cancer 2000, 36: 1681-1694.
119. Bartlett JMS, Stirling D. A short history of the polymerase chain reaction. PCR Protocols 2003, 226: 3-6.
120. Iinuma H, Okimaga K, Adachi M, Suda K, Sekine T, et al. Detection of tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele-specific amplification of p53 and K-ras genes in patients with colorectal cancer. Int J Cancer 2000, 89: 337-344.
121. Liu Yin JA, Grimwade D. Minimal residual disease evaluation in acute myeloid leukaemia. Lancet 2002, 360: 160-162.
122. Corchero JL, Villverde A. Biomedical application of distally controlled magnetic nanoparticles. Trends Biotechnol 2009, 27: 468-476.
123. Herr JK, Smith JE, Medley CD, Shangguan D, Tan W. Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells. Anal Chem 2006, 78: 2918-2924.
124. Smith JE, Medley CD, Tang Z, Shangguan D, Lofton C, et al. Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Anal Chem 2007, 79: 3075-3082.
125. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346: 816-820.
126. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249: 505-510.
127. Pavlov V, Xiao Y, Shlyahovsky B, Willner I. Aptamer-functionalized Au nanoparticles for the amplified optical detection of thrombin. J Am Chem Soc 2004, 126: 11768-11769.
128. Cheung VG, Morley M, Aguilar F, Massimi A, Kucherlapati R, et al. Making and reading microarrays. Nat Genet 1999, 21: 15-19.
129. Lockhart DJ, Dong H, Byrne MC, Follette MT, Gallo MV, et al. Expression monitoring by hybridization to high-density oligionucleotide arrays. Nat Biotechnol 1996, 14: 1675-1680.
130. Fulton RJ, McDade RL, Smith PL, Kienker LJ, Kettman JR Jr. Advanced multiplexed analysis with the FlowMetrix™ system. Clin Chem 1997, 43: 1749-1756.
131. Chung TD, Kim HC. Review: recent advances in miniaturized microfluidic flow cytometry for clinical use. Electrophoresis 2007, 28: 4511-4520.
132. Nicewarner-Peña SR, Freeman RG, Reiss BD, He L, Peña Walton ID, et al. Submicrometer Metallic Barcodes. Science 2001, 294: 137-141.
133. Nam J, Thaxton CS, Mirkin CA. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. science 2003, 301: 1884-1886.
134. Thaxton CS, Hill HD, Georganopoulou DG, Stoeva SI, Mirkin CA. A biol-bar-code assay based upon dithiothreitol-induced oligonucleotide release. Anal Chem 2005, 77: 8174-8178.
135. Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ. A DNA-based method for rationally assembling nanoparticles into macroscopic materials. Nature 1996, 382: 607-609.
136. Elghanian R, Storhoff JJ, Mucic RC, Letsinger RL, Mirkin CA. Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles. Science 1997, 277: 1078-1080.
137. Park SJ, Taton TA, Mirkin CA. Array-based electrical detection of DNA with nanoparticle probes. Science 2002, 295: 1503-1506.
138. Stiriba SE, Frey H, Haag R. Dendritic polymers in biomedical applications: from potential to clinical use in diagnostics and therapy. Angew Chem Int Ed Engl 2000, 41: 1329-1334.
139. McCarthy TD, Karellas P, Henderson SA, Giannis M, O'Keefe DF, et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm 2005, 2: 312-318.
140. Wiener EC, Brechbiel MW, Brothers H, Magin RL, Gansow OA, et al. Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn Reson Med 1994, 31: 1-8.
141. Kobayashi H, Kawamoto S, Star RA, Waldmann TA, Tagaya Y, et al. Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. Cancer Res 2003, 63: 271-276.
142. Tomalia DA, Reyna LA, Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans 2007, 35: 61-67.
143. Sumer B, Gao J. Theranostic nanomedicine for cancer. Nanomedicine 2008, 3: 137-140.
144. American Cancer Society. Breast Cancer Facts & Figure 2009-2010. Atlanta: American Cancer Society, 2009.